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EDITORIAL COMMENTARY
Partners in Crime:
Fledgling Tumors Hijack Inflammation
Balamurugan Kuppusamy and Howard A. Young
While inflammation is a normal physiological re-sponse after tissue injury, the chemicals/mediators that
are released by the damaged tissue can be toxic to the cells.
This underlying inflammation increases the likelihood of
cellular DNA damage and aberrant cell growth (Kiraly and
others 2015). In this scenario, inflammation functions as a
‘‘behind-curtain factor’’ for many disorders. Cancer has long
been known to be closely tethered to inflammation. Wide-
spread evidence shows that inflammatory diseases such as
colitis, pancreatitis, and hepatitis make their respective or-
gans highly susceptible to eventual cancer development
(Shalapour and Karin 2015). However, other studies have
shown that in due course, a growing cancer starts recruiting
and relying on various mediators of inflammation to promote
angiogenesis, further proliferating, metastasizing, and sub-
verting the innate and adaptive immune response (Chan and
others 2012). While we continue to ponder the chicken or
egg scenario of how cancer and inflammation are related, the
critical role inflammation plays in cancer progression cannot
be denied. For example, some studies demonstrate that anti-
inflammatory drugs such as aspirin not only act by reducing
inflammation-related disorders, but also decrease the risk of
colon cancer and gastrointestinal cancers. In colon cancer,
aspirin specifically decreased the incidence of polyps, in-
cluding advanced polyps, which are the precursors to colo-
rectal cancer (Husain and others 2002; Wang and others
2018). However, experimental data from other cancers, in-
cluding breast cancer, are not very promising, largely due to
the differences in the inflamed tumor microenvironment
(Strasser-Weippl and others 2018). Therefore, understanding
the intricate cellular signaling pathways and the players in-
volved in the smoldering inflammatory tumor microenvi-
ronment is paramount to identifying new strategies for the
better management of cancers.
In this special issue, several leaders in the field discuss
the latest developments in our understanding of cancer-
associated inflammation, with a focus on the role of in-
flammatory cytokines and interferons. Emphasis is also
placed on identifying opportunities and developing road
maps for novel treatment approaches to combine im-
munotherapies with direct modulation of cytokine levels in
the host.
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Dr. Howard Young obtained his PhD in microbiology at the University of Washington and carried
out postdoctoral research at the National Cancer Institute (NCI) under Drs. Edward Scolnick and
Wade Parks. He was a member of the Laboratory of Molecular Immunoregulation at NCI from
1983 to 1989 prior to joining the Laboratory of Experimental Immunology in 1989. He was
President of the International Society for Interferon and Cytokine Research (2004–2005) and
served as Chair of the Immunology Division of the American Society for Microbiology. He has
also served as Chair of the National Institutes of Health (NIH) Cytokine Interest Group and Co-
Chair of the NIH Immunology Interest Group. He is a three-time recipient of the NIH Director’s
Award for Mentoring (2000, 2006, and 2018), and in 2006 he received the National Public Service
Award. Dr. Young has expertise in the regulation and characterization of cytokine gene expression
with a special emphasis on interferons. The Young laboratory has as its major focus how disruption
of the control of interferon-g gene expression during development and maturation of the cellular
immune system impacts the host inflammatory response and the development of autoimmune
disease and cancer. His laboratory has developed a mouse model of chronic interferon-g expression
that results in three different autoimmune diseases resembling lupus, aplastic anemia, and primary
biliary cholangitis. This model may provide new insight into the initiation and progression of these
diseases.
Balamurugan Kuppusamy, PhD
Dr. Balamurugan Kuppusamy obtained his PhD from the University of Madras, Chennai, India.
Dr. Kuppusamy pursued his postdoctoral studies at the University of Zurich, Switzerland, and at the
NCI. Since March 2015, he has served as a staff scientist in the Laboratory of Cell and Devel-
opmental Signaling (NCI/CCR). Dr. Kuppusamy is a recipient of the NCI Cancer Genetics and
Signaling Fellowship. In 2011 and 2012, he received the NIH ‘‘Fellows Award for Research
Excellence’’ and NCI Fellows and Young Investigators ‘‘Outstanding Achievement in Science
Award,’’ respectively. In 2015, he was awarded a research grant from the METAvivor Foundation
to study signaling pathways in inflammatory breast cancer, an aggressive subtype of breast cancer.
Dr. Kuppusamy has published 20+ peer-reviewed research articles. His areas of expertise include
hypoxia, signal transduction, cancer stem cells, mouse models, breast cancer, CEBPD transcription
factor, FBXW7, and inflammation.
Lead Authors
Thomas A. Waldmann, MD
Dr. Waldman received his MD degree from Harvard Medical School. Following an internship at
Massachusetts General Hospital, he joined the Metabolism Branch of the National Cancer Institute
(NCI) in 1956. Since 1973, he has been Chief of the Metabolism Branch, CCR of the NCI, National
Institutes of Health (NIH), now named the Lymphoid Malignancies Branch. Over the past quarter
century, Dr. Waldmann’s work has focused on the biology of interleukin-2 (IL-2) and IL-15 with
implications for cancer therapy and vaccine design. He reported the production of the monoclonal
antibody anti-Tac that identified the IL-2 receptor alpha subunit. The humanized form of this anti-
body, daclizumab (Zenapax), was approved by the Food and Drug Administration (FDA) for use in
the prevention of renal allograft rejection and is of value in the treatment of multiple sclerosis.
Dr. Waldmann showed that although IL-2 and IL-15 that he co-discovered have heterotrimeric
receptors with two subunits in common, these two cytokines have contrasting roles in the adaptive
immune response. The unique role of IL-2 is in the elimination of self-reactive T cells to prevent
autoimmunity. By contrast, IL-15 is dedicated to the prolonged maintenance of memory T-cell
responses to invading pathogens. Dr. Waldmann has taken advantage of this difference to produce IL-
15 under current Good Manufacturing Practice for use in the treatment of patients with metastatic
malignant melanoma and renal cell cancer. Furthermore, he is incorporating IL-15 and its receptor,
IL-15R alpha, in molecular vaccines for cancer and AIDS. Dr. Waldmann has been awarded the Lila
Gruber Cancer Research Award, the CIBA-Geigy Drew Award in Biomedical Research, the Milken
Family Medical Foundation Distinguished Basic Scientist Award, the Artois-Baillet Latour Health
2 EDITORIAL COMMENTARY
Prize, the Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research, the Paul
Ehrlich Medal, Paul Ehrlich Institute, the Debrecen Prize in Molecular Medicine, and the AAI-Dana
Foundation Award in Human Immunology Research. He has been elected as a member of the
National Academy of Sciences USA, American Academy of Arts and Sciences, the Institute of
Medicine of the NAS, Association of American Physicians, and the Hungarian Academy of Sciences,
and is an Honorary Fellow of the Royal Society of Medical Sciences (United Kingdom). Further-
more, he has been appointed as a NIH Distinguished Investigator.
Kevin C. Conlon, MD
Dr. Kevin Conlon graduated from Rush Medical College and completed his residency in Internal
Medicine at Rush University Medical Center (RUMC). After serving as Chief Medical Resident at
RUMC, he received his medical oncology training at the NCI and subsequently joined the Biological
Response Modifier Program at the Frederick Cancer Research Center (BRMP/FCRF) to continue his
translational immunotherapy research. After leaving the BRMP, Dr. Conlon was a medical officer at
the Center for Biologics Evaluation and Research (CBER) at the FDA and later a clinical director of
the IL-12 program at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon joined the Rush
University Section of Medical Oncology in 2000 to continue his clinical and translational immu-
notherapy efforts as the Director of Clinical Research and the Oncology Inpatient Unit for the section.
He returned to the NCI in 2009, initially joining the Investigational Drug Branch of Cancer Therapy
Evaluation Program (IDB/CTEP), and since 2011 he has been responsible for directing clinical trials
derived from the preclinical research of the laboratory of Dr. Thomas A. Waldmann, the chief of the
Lymphoid Malignancy Branch (LyMB). He has been the principal investigator on many of the
Branch’s IL-15 and other clinical trials. While at the BRMP, Dr. Conlon worked in the Laboratory of
Dr. Augusto Ochoa evaluating adoptive cellular immunotherapy strategies, and later in collaboration
with Drs. Howard Young and John Ortaldo, he examined functional differences in T-cell subsets.
These laboratory investigations defined differences in cytokine secretion, chemokine production, as
well as differences in NF-kB family transcriptional factor signaling for CD4 and CD8 naı̈ve and
memory subsets. Dr. Conlon also continued to assess preclinical immunotherapy models in collab-
oration with Drs. William Murphy and Robert Wiltrout. His clinical efforts at the BRMP included
pilot studies with anti-CD3 activated T cells and recombinant human cytokines. In his time at the
Genetics Institute, RUMC Medical Oncology, and since returning to the NCI, Dr. Conlon’s research
focus has been clinical immunotherapy trials. Under his direction, the Clinical Trials Team completed
the first-in-human trial with recombinant human IL-15 (rhIL-15) and continues to develop combi-
nation immunotherapy trials with rhIL-15. He is also collaborating with Dr. Liyanage Perera of
LyMB to develop cellular immunotherapy trials with chimeric antigen receptor T cells against a
variety of tumor target antigens. The other focus of Dr. Conlon’s clinical research is HTLV-1 related
adult T-cell leukemia lymphoma, which is a continuation of Dr. Waldmann’s long-standing research
interest in immune-based treatments for this disease.
Ahmed Lasfar, PhD
Dr. Ahmed Lasfar is a member of the Cancer Institute of New Jersey and Principal Investigator and
a faculty member at Ernest Mario School of Pharmacy, Rutgers University, New Jersey. He serves
as editor, board member, and reviewer of several international journals and foundations. Dr. Lasfar
graduated in France from Paris Rene Descartes University in medical and applied science. He
completed his doctoral studies in immunology at Paris Diderot University and his postdoctoral
training in cancer immunology at Robert Wood Johnson Medical School, New Jersey.
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M. Raza Zaidi, PhD
M. Raza Zaidi received his PhD in biochemistry and molecular biology from Robert Wood Johnson
Medical School, Rutgers University, New Jersey, and completed his postdoctoral training at Co-
lumbia University and the NCI. He is currently an associate professor at the Fels Institute for
Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University.
The overarching goal of his research program is to elucidate the molecular mechanisms of ultra-
violet radiation (UV)-induced melanomagenesis. In this respect, his specific interest is in gene–
environment–microenvironment interactions and how inflammatory and epigenetic mechanisms
play pro-melanomagenic roles in the context of UV insult to the skin.
Jorge Morales-Montor, PhD
Dr. Jorge Morales-Montor is a full-time professor at the Departamento de Inmunologı́a, Instituto de
Investigaciones Biomèdicas, Universidad Nacional Autonoma de México. He is the chief editor of
Advances in Neuroirmmune Biology and member of the editorial board of 20 journals. He has
published more than 120 scientific articles. One of his contributions, published in the Journal of
Interferon and Cytokine Research, is the journal’s most downloaded and cited article since 2015.
He is a member of the Mexican Academy of Sciences, the Latin America Academy of Sciences, the
New York Academy of Sciences, and the American Association of Immunologists.
Ayten Nalbant, PhD
After graduating from Istanbul University with a biology major, Dr. Ayten Nalbant did a master’s
and PhD at the University of Southern California, Los Angeles. After completing her doctoral
studies, Dr. Nalbant began working as an assistant professor in the Department of Molecular
Biology and Genetics at the Izmir Institute of Technology (IYTE), and she continues to work at this
institution. She has also worked as acting head and head of the Molecular Biology and Genetics
Department and as deputy dean of the Faculty of Science at the IYTE. She teaches undergraduate
and graduate courses in immunology, cell biology, signal transduction, and apoptosis. She is a
founder and director of the molecular immunology laboratory at the Molecular Biology and Ge-
netics Department of IYTE. Dr. Nalbant’s ongoing scientific research is in the field of molecular
cellular immunology, in particular differentiation of T helper 17 cells and immune response reg-
ulation. The research in her laboratory is supported by the Scientific and Technological Research
Council of Turkey. She is a principle investigator of the 1001-Scientific and Technological Re-
search Projects funding program. She has published numerous national and international abstracts
and research and review articles in T-cell immunology.
Jaewoo Hong, PhD
Dr. Jaewoo Hong graduated from Konkuk University in Seoul, South Korea, with a DVM in 2006
and a PhD in immunology in 2012. He then completed a dissertation on cytokine immunology. He
joined Dr. Richard Lee’s lab at Brigham and Women’s Hospital/Harvard Medical School in 2012
as a postdoctoral research fellow to study the role of IL-33 in the cardiovascular system. He joined
Dr. Charles Lin’s lab at the NCI in 2013 as a Cancer Research Training Award fellow.
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Julio Valencia, MD
Dr. Julio C. Valencia is a staff scientist at the Cancer and Inflammation Program (CIP), NCI, in
Frederick, Maryland. He earned a MPH degree (2018) from the University of Maryland—College
Park and a MD degree (1997) from the Universidad Nacional Mayor de San Marcos (UNMSM),
Lima, Peru. He began actively working on the biology of interferons (IFNs) and autoimmunity with
Dr. Howard Young after joining the CIP group late in 2014. Previously, Dr. Valencia worked on
several areas related to skin biology, pigmentation, and melanoma as part of the Pigment Cell
Biology Section in the Laboratory of Cell Biology, NCI, in Bethesda, Maryland. There,
Dr. Valencia explored the effects of IFNs on skin cells and pigmentation. In 2006, Dr. Valencia
spearheaded the completion of the first melanosome proteome that identified novel biomarkers for
melanoma and elucidated the role of melanosomes in drug resistance (2009). From 2012 to 2015,
he served as an elected council member of the Pan American Society of Pigment Cell Research
(2013–2015) and served as co-chair of the Pigment Cell Interest group at the NIH (2012–2014).
Currently, Dr. Valencia’s focus is on understanding cancer development and immunotherapy op-
tions in the context of autoimmunity. The mini-review presented here covers the adaptation
mechanisms acquired by immune cells during autoimmunity, current and experimental anticancer
therapies, and the most common preclinical mouse models available for research on autoimmune
diseases.
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